VISCHER has advised St. Clara AG and the Ingenbohl Monastery. Bratschi advised and represented the University Hospital Basel in the merger proceedings before the COMCO. The...
University Hospital Basel Acquires St. Claraspital AG
Danaher Corporation’s Acquisition Of Genedata AG
VISCHER’s advised Genedata on the deal. Genedata AG, a leading provider of software solutions for biopharmaceutical R&D, has been acquired by Danaher Corporation (NYSE: DHR), a...
Memo Therapeutics AG’s CHF20 Million Additional Series C Financing Round
VISCHER advised Ysios Capital and Kurma Partners. Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised...
Nouscom’s €67.5 Million Oversuscribed Series C Financing Round
Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
Medartis’ CHF 18 Million Acquisition of Additional Stake in KeriMedical
VISCHER advised Medartis on the deal. Medartis (SIX: MED), a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private...
Resistell AG’s CHF 8.5 Million Series B Financing Round First Tranche
Vischer advised Resistell AG on the deal. Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another...
European Biotech Acquisition’s $200 Million Combination With Oculis
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
Sunrise’s Acquisition of EBL’s Telecom Division
VISCHER advised EBL on the deal. Swiss full-service provider Sunrise has signed an agreement to acquire the telecom business of utility firm EBL. EBL has been...
Novaremed’s Option and License Agreement With NeuroFront
VISCHER advised Novaremed AG on the deal. Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience...
Novaremed’s Acquisition of Metys Pharmaceuticals
VISCHER AG advised Novaremed on the deal. Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through...
Haya Therapeutics’ CHF 18 Million Seed Round
VISCHER advised Haya Therapeutics SA on all legal issues related to the financing round. HAYA Therapeutics SA, a company developing precision medicines that target tissue and...
Haya Therapeutics’ CHF 18 Million Seed Round
VISCHER advised Haya Therapeutics SA on all legal issues related to the financing round. HAYA Therapeutics SA, a company developing precision medicines that target tissue and...